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Abstract
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One of the hallmarks of cancer is the ability to generate and withstand unusual levels of oxidative
stress. In part, this property of tumor cells is conferred by elevation of the cellular redox buffer
glutathione. Though enzymes of the glutathione synthesis and salvage pathways have been
characterized for several decades, we still lack a comprehensive understanding of their
independent and coordinate regulatory mechanisms. Recent studies have further revealed that
overall central metabolic pathways are frequently altered in various tumor types, resulting in
significant increases in biosynthetic capacity, and feeding into glutathione synthesis. In this
review, we will discuss the enzymes and pathways affecting glutathione flux in cancer, and
summarize current models for regulating cellular glutathione through both de novo synthesis and
efficient salvage. In addition, we examine the integration of glutathione metabolism with other
altered fates of intermediary metabolites, and highlight remaining questions about molecular
details of the accepted regulatory modes.
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Introduction
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Glutathione is a critical low molecular weight thiol that participates in numerous cellular
functions in mammalian systems (Figure 1). Intracellular glutathione concentrations range
between 0.5 and 10 mM whereas extracellular glutathione concentrations are significantly
lower, with estimated values in the micromolar range (Meister and Anderson, 1983).
Glutathione is predominantly found in its reduced state (GSH) or as its most commonly
observed oxidation product, GSSG, which is formed from two molecules of glutathione
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linked by a disulfide bond. The GSH/GSSG redox system maintains an overall reducing
environment in the cell, with GSH/GSSG ratios ranging from 30:1 to >100:1 in the cytosol,
nucleus, and mitochondria. This ratio is considerably lower in the endoplasmic reticulum
with values of 1:1 to 3:1 reported, conditions in which disulfide bonds are generated in
proteins traversing the secretory pathway (Dickinson and Forman, 2002; Lu, 2009, 2013;
Meister and Anderson, 1983). GSSG is converted to its reduced state by glutathione
reductase, using NADPH generated primarily by the pentose phosphate pathway (Figure 2).

Author Manuscript

One of the primary functions of glutathione is cellular detoxification. Glutathione
transferases (GST) conjugate the tripeptide via its thiol group to endogenous and exogenous
electrophilic compounds (Hayes et al., 2005; Mannervik, 2012; Townsend and Tew, 2003),
reducing their reactivity and facilitating their clearance from the cell via members of the
multidrug resistance associated protein family (Bachhawat et al., 2013). A comprehensive
review of this topic can be found in this volume. The selenocysteine-containing glutathione
peroxidases use glutathione to reduce H2O2 or lipid peroxides to water or their
corresponding alcohols respectively, generating oxidized glutathione (Brigelius-Flohe and
Maiorino, 2013). The glyoxalase system, composed of glyoxalase I and glyoxalase II, also
requires GSH to detoxify methylglyoxal, glyoxal and other α-oxoaldehydes (Sousa Silva et
al., 2013). However, there is no net oxidation of the cofactor. GSH has also been shown to
be involved in the sequestration and transport of metals, including mercury, zinc and copper
(Wang and Ballatori, 1998).

Author Manuscript

In addition to cellular detoxification, members of MAPEG (membrane-associated proteins in
eicosanoid and glutathione metabolism) family, which are distantly related to glutathione
transferases, contribute to eicosanoid biosynthesis (Hayes et al., 2005). Prostaglandin E
synthase converts prostaglandin H2 to prostaglandin E2, using GSH as a cofactor.
Leukotriene C4 synthase adds GSH to leukotriene A4 to produce leukotriene C4 (Lam et al.,
1994; Welsch et al., 1994; Yoshimoto et al., 1985). The γ-glutamyl peptide bond of the
attached glutathione is cleaved by another glutathione metabolic enzyme, γglutamyltranspeptidase (GGT5), to generate leukotriene D4 (Carter et al., 1998). Glutathione
is also used in the storage and transport of cysteine (Lieberman et al., 1996). A different
isozyme of γ-glutamyltranspeptidase (GGT1) initiates the enzymatic cleavage of
extracellular glutathione, leading to the degradation of glutathione to its component amino
acids (Hanigan and Ricketts, 1993). Cysteine derived from extracellular glutathione is then
imported into the cell and used for protein and intracellular glutathione production
(discussed below).

Author Manuscript

The glutaredoxin enzyme family (Lillig et al., 2008) is dependent on the GSH pools
maintained by glutathione reductase. Glutaredoxins, also known as thiol transferases,
catalyze the reversible glutathionylation of protein thiol groups. Dithiol glutaredoxins have
an active site Cys-X-X-Cys motif and reduce selected protein disulfides at the expense of
two molecules of GSH, generating GSSG. Monothiol glutaredoxins, such Grx5 in humans,
retain the N-terminal cysteine residue of this motif. Glutaredoxins have been shown to be
critical in iron-sulfur cluster assembly, and to catalyze the reduction of dehydroascorbate to
ascorbate.
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Given the diverse functions of glutathione, from involvement in signaling pathways to
cellular detoxification, aberrant glutathione metabolism has been observed in multiple
disease states. GSH levels are known to diminish with increased age and these reduced GSH
levels are correlated with increased oxidative damage. In the human eye, GSH levels have
been shown to drop significantly and this diminution may contribute to cataract formation
(Fan et al., 2012; Harding, 1970). Similarly, brain GSH levels are lower in patients suffering
from neurodegenerative diseases including Parkinson’s and Alzheimer’s and psychiatric
disorders such as schizophrenia (Currais and Maher, 2013).

Author Manuscript

A recent comprehensive study evaluated previously reported GSH levels in numerous cancer
types relative to normal controls (Gamcsik et al., 2012). In general, GSH levels were found
to be higher in many cancer types, including head and neck, breast, ovarian, colorectal, and
lung. This in agreement with the long held hypothesis that rapidly dividing tumor cells
experience increased levels of oxidative stress and require higher levels of GSH. In addition,
elevated GSH in concert with higher glutathione transferase expression protects these cells
against administered chemotherapeutic agents (Hayes et al., 2005; Townsend and Tew,
2003). However, GSH levels tended to be lower in other cancers, including liver and brain,
suggesting the contributions of GSH to disease progression may be more complex than
anticipated (Gamcsik et al., 2012).

Glutathione Homeostasis

Author Manuscript

GSH biosynthesis requires sufficient quantities of glutamate, cysteine, and glycine to
maintain appropriate levels of the tripeptide. As discussed below, availability of these
precursors reflects the overall metabolic status of the cell. Meister and co-workers proposed
a γ-glutamyl cycle (Figure 3) to highlight the central role of GSH in amino acid uptake
(Meister, 1973, 1974; Orlowski and Meister, 1970). In this proposed pathway, GSH is
synthesized by the sequential action of two ATP-dependent ligases, glutamate cysteine
ligase (GCL) and glutathione synthetase (GS). Human GCL, also known as γglutamylcysteine synthetase, is composed of a 73 kDa catalytic subunit (GCLC) and a 31
kDa regulatory subunit (GCLM). GCL catalyzes the formation of a peptide bond between
the γ-carboxylate of glutamate and the α-amino group of cysteine (Orlowski and Meister,
1971) and is the rate-limiting enzyme in GSH biosynthesis. GS then couples the αcarboxylate of γ-glutamylcysteine to the α-amino group of glycine to produce glutathione
(Snoke and Bloch, 1955).
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Although several plasma membrane transporters capable of importing intact glutathione
have been identified (reviewed in (Bachhawat et al., 2013)), the primary means of importing
glutathione into a cell appears to be through a scavenging pathway (Lieberman et al., 1996;
Lu, 2013). The salvage of extracellular glutathione is initiated by γ-glutamyltranspeptidase
(GGT), a membrane anchored glycosylated enzyme that cleaves the γ-glutamyl peptide bond
of glutathione (Ikeda and Taniguchi, 2005; Keillor et al., 2005; Kinlough et al., 2005). The
enzyme reaction proceeds via a γ-glutamyl enzyme intermediate, in which the γ-glutamyl
moiety is covalently linked to the threonine nucleophile at the active site. The released
cysteinylglycine is then cleaved to its component amino acids by a dipeptidase (Dickinson
and Forman, 2002; Lu, 2013), and imported into the cell. The acyl-enzyme intermediate of
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γ-glutamyltranspeptidase is resolved by the nucleophilic attack of water or another amino
acid/peptide to generate glutamate or a new γ-glutamyl peptide, respectively. Studies by
Meister and colleagues suggested that the transpeptidation reaction was preferred and
facilitated the import of amino acids into the cell (Meister, 1974; Orlowski and Meister,
1970; Thompson and Meister, 1975). γ-Glutamylcyclotransferase (GGCT) cyclizes the γglutamyl moiety of the imported peptides to produce 5-oxoproline, also known as
pyroglutamate or pyrrolidone carboxylate, and liberates the coupled amino acid or peptide
(Board et al., 1978; Oakley et al., 2008; Orlowski et al., 1969). To complete the proposed
cycle, human 5-oxoprolinase (OPLAH), a 275 kDa homodimer, couples ATP hydrolysis to
the opening of the ring structure to generate glutamate (Van der Werf et al., 1971; Van Der
Werf et al., 1974).

Author Manuscript
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Now that each of the enzymes of the cycle has been identified and characterized, studies that
address the concerted functionality of this pathway can be undertaken. Although the
requirement of GCL and GS for glutathione biosynthesis is well documented, the
contributions of the salvage pathway enzymes remain open for debate. Genome sequencing
has led to the identification of close homologues of glutathione salvage enzymes in
organisms that do not appear to synthesize glutathione and therefore may have alternate
functions, as discussed below. Other studies suggest the cycle is not as straightforward as
proposed. For example, although the transpeptidase activity of GGT was proposed to be
required for amino acid import (Meister, 1973; Orlowski and Meister, 1970; Sekura and
Meister, 1974), GGT null mice produced viable offspring (Lieberman et al., 1996). In
addition, the observed phenotypic changes could be ameliorated by supplementation with Nacetylcysteine, a cysteine surrogate, suggesting that the primary function of GGT is to
liberate cysteine from glutathione produced in the liver for biosynthetic purposes in
peripheral tissue. Thus, regulation of glutathione metabolism is more complex than
originally suggested and further work is needed to understand the contributions of
glutathione to disease progression.
Glutathione Biosynthesis

Author Manuscript

Glutamate cysteine ligase—Human GCL (Figure 4) catalyzes the rate-limiting step in
glutathione biosynthesis and its activity is subject to multiple levels of regulation (Griffith
and Mulcahy, 1999; Lu, 2013). Transcriptional regulation of the catalytic and regulatory
subunits of the enzyme is mediated through several established pathways including Nrf2Keap1 and NFκB (Griffith and Mulcahy, 1999; Lu, 2013). GCL is also extensively
regulated at the protein level. The enzyme is feedback inhibited by glutathione (Richman
and Meister, 1975), and is allosterically activated by addition of the regulatory subunit
(GCLM) to the catalytic subunit (GCLC). The resulting heterodimer is 2 – 5 fold more
efficient in the production of glutathione, due to improved catalytic efficiency of the enzyme
and alleviation of feedback inhibition by glutathione (Backos et al., 2011; Lu, 2013). The
relative ratio of GCLM/GCLC differs considerably from tissue to tissue, and this site
specific ratio may largely dictate glutathione production (Chen et al., 2005). Formation of
the GCL heterodimer has been examined in human and closely related systems, but the
molecular details of how complex formation improves flux through the biosynthetic
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pathway are not clear. This section summarizes published regulatory models and addresses
associated limitations that leave the models open to further interpretation.
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Redox regulation: An attractive model of redox regulation of complex formation was
postulated based on the observation of a disulfide linked species in the early preparations of
the enzyme purified from rat kidney (Huang et al., 1993; Seelig et al., 1984). The model
suggested that at lower reduced glutathione concentration, a disulfide bond would form
between the catalytic and modifier subunits and increase activity to produce more
glutathione. Once glutathione levels were restored, the disulfide bond would be reduced, the
complex would no longer be stabilized, and flux through the glutathione biosynthetic
pathway would slow. However, the identities of these cysteine residues have not been
established. Studies of Drosophila GCL indicate that an intersubunit disulfide bond can be
formed but it is not required for allosteric activation of the enzyme (Fraser et al., 2003). The
disulfide linked species is a relatively minor fraction of the total enzyme in mouse tissue,
and the holoenzyme forms readily without any oxidation (Krejsa et al., 2010). Unpublished
work from our group using recombinant GCLC and GCLM suggests that although a
disulfide can form, it is not required for stabilization of the human GCLC/GCLM complex
or activation of the enzyme. However, agents that stimulate oxidative stress (e.g. pherone,
H2O2) have been shown to rapidly increase GCL activity independently of increased
enzyme expression suggesting that other cysteine oxidation events may indeed regulate GCL
activity (Krejsa et al., 2010; Ochi, 1995, 1996). However, oxidized species of GCL have not
been detected.

Author Manuscript
Author Manuscript

Phosphorylation: Additional post-translational modifications of human GCL have been
reported. Hormone-mediated phosphorylation of rat liver GCL resulted in modest but
significant reductions of enzymatic activity and correspondingly lower levels of glutathione
(Lu et al., 1991). Subsequent studies indicated that protein kinase A (PKA), protein kinase C
(PKC) and Ca2+/calmodulin-dependent kinase II (CKII) could each phosphorylate the
catalytic subunit of GCL in vitro, resulting in an approximately 20% reduction in Vmax (Sun
et al., 1996). Although the precise site(s) of phosphorylation were not identified, the authors
suggested that Thr 132, Thr 188, Ser 331, Thr 506, Ser 567 and Ser 591 are potential CKII
target sites. Examination of a homology model of GCLC generated using the Phyre2
webserver (Kelley and Sternberg, 2009) suggests that, with the exception of Ser 591, each of
these residues is relatively solvent accessible and thus a possible candidate for
phosphorylation. Of the remaining residues, Thr 188 (Figure 4) is located on the periphery
of the enzyme active site and its phosphorylation could impact substrate binding and/or
catalysis. However, direct identification of specific phosphorylation sites has not been done
to establish the biological significance of phosphorylation given the relatively modest, yet
significant, reduction in enzymatic activity.
Proteolysis: During apoptosis, caspase-3 cleaves the catalytic subunit of GCL into 60 kDa
and 13 kDa fragments, and this modification may contribute to reduced cellular GSH levels
observed during this process (Siitonen et al., 1999). The site of proteolytic cleavage was
mapped to Asp 499 by mutational analysis (Franklin et al., 2002). In a recent review, the
authors indicated that in vitro cleavage of recombinant GCLC by caspase-3 did not impact
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the overall structure of GCLC or its enzymatic activity (Franklin et al., 2009). Examination
of a homology model of human GCL (Willis et al., 2011) indicates that Asp 499 is predicted
to be in an extended surface exposed loop remote from the enzyme active site and that
cleavage would not directly impact the core structural features (Figure 4). Thus, it is unclear
how significant this observation is, with respect to maintenance of glutathione levels.

Author Manuscript

Lipid adducts: A reactive product of lipid peroxidation, 4-hydroxy-2-nonenal, was shown
to rapidly increase GCL activity and GSH levels in the lung adenocarcinoma line, A549
(Backos et al., 2011). A corresponding increase in isolated catalytic subunit activity was
observed with 4-hydroxy-2-nonenal treatment. Modification of Cys 553 by 4-hydroxy-2nonenal at a 100-fold molar excess resulted in an approximately two-fold increase in Vmax
and modest reductions in the Km values for glutamate and ATP. Comparable results were
observed with another cysteine modifying agent, N-ethylmaleimide, suggesting that any
number of modifications of this cysteine residue may activate the enzyme. Within the
regulatory subunit, Cys 35 was identified as the primary site of modification by 4hydroxy-2-nonenal. Isolated subunits when pre-incubated with 4-hydroxy-2-nonenal had
impaired ability to form the holoenzyme. Modification of Cys 553 of GCLC impaired but
did not completely block complex formation whereas modification of Cys 35 of GCLM
precluded subunit association. A telling observation was that in the preformed complex,
only Cys 35 was reactive with 4-hydroxy-2-nonenal, suggesting that Cys 553 may be
inaccessible to chemical modification in the complex. Conversely, Cys 35 is solvent
accessible in either case and is considerably more reactive than any of the other 5 cysteine
residues of GCLM. These studies clearly indicate that Cys 553 of GCLC and Cys 35 of
GCLM are reactive towards alkylating agents and these modifications impact GCL function
in vitro, but direct adduct formation was not demonstrated in cell lysates or tissue samples.

Author Manuscript
Author Manuscript

Glycation: Recently, glycation of GCLM and GCLC has also been reported and this posttranslational modification was shown to impact heterodimer formation, with modest effects
on kinetic constants (Backos et al., 2013). Pre-treatment of individual subunits with 2deoxy-D-ribose as a chemical modifier impaired heterodimer formation, but treatment of the
holoenzyme had no apparent effect on oligomeric state. Extended incubations with 30 mM
2-deoxy-D-ribose (24 h) resulted in decreased activities for GCLC alone and the
holoenzyme complex with no significant effects on the Km values for each substrate.
Similarly, Ki values for glutathione remained unchanged. These results suggest that
glycation inactivated the enzyme directly but slowly over time. As with 4-hydroxy-2nonenal modification, glycation products of GCLC and GCLM were not identified in
biological samples. Similarly, attempts to identify the sites of modification using
recombinant protein were unsuccessful so it is difficult to assign functional significance to
this observation. Cys 553 has been previously implicated in GCL complex formation (Tu
and Anders, 1998) and thiol modification at this position may be an important mode of
regulation. However, direct evidence for modification at Cys 553 under physiologically
relevant conditions was not shown.
Glutathione Synthetase—GS is largely overlooked when considering the regulation of
cellular glutathione levels. Human GS is a homodimeric enzyme that has been extensively
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characterized using both structural (Gogos and Shapiro, 2002) and kinetic approaches
(Brown et al., 2011; Dinescu et al., 2010; Dinescu et al., 2004; Luo et al., 2000; Slavens et
al., 2011; Snoke and Bloch, 1955). It is a member of the ATP-grasp superfamily (Fawaz et
al., 2011) and rapidly catalyzes the ligation of γ-glutamylcysteine and glycine to generate
glutathione. Based on these kinetic studies, flux through the glutathione biosynthetic
pathway is thought to be largely controlled by GCL activity (Backos et al., 2011; Lu, 2013).
Unlike GCL, GS is not feedback inhibited by GSH nor does it have an associated regulatory
subunit. Furthermore, there have been no validated reports of post-translational modification
of GS having any impact on enzymatic activity. As such, GS activity appears to be primarily
controlled at the level of transcription and substrate availability.
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GSH in development—Targeted disruption of either glutathione synthetase (Winkler et
al., 2011) or the catalytic subunit of GCL (Dalton et al., 2000; Shi et al., 2000) results in an
embryonic lethal phenotype in null homozygous mice, demonstrating the central importance
of glutathione in development. Although GS null mice were not viable, heterozygous mice
had no discernable phenotype other than a 50% reduction both in protein levels and
enzymatic activity. Glutathione levels were normal and γ-glutamylcysteine did not
accumulate, supporting the assertion that GCL activity is typically the limiting factor in
glutathione production (Winkler et al., 2011). Similarly, heterozygous GCLC-deficient mice
had no overt phenotype, but had approximately two-fold reductions in GCLC levels and
GCLC activity (Dalton et al., 2000; Shi et al., 2000). However, glutathione levels were only
reduced by approximately 20%, suggesting other compensatory mechanisms in
heterozygous mice (Dalton et al., 2000). A liver-specific targeted disruption of GCLC did
not impact embryogenesis or development, but severe abnormalities of the liver manifested
within four weeks of birth (Chen et al., 2007). Plasma glutathione levels were reduced
dramatically, although glutathione levels in peripheral tissues remained relatively
unchanged. In contrast, GCLM deficient mice have less dramatic phenotypes (Yang et al.,
2002). Without its regulatory subunit, GCLC activity and glutathione levels are reduced to
between 10 – 40% of wild-type mice depending on the tissue, but no overt phenotype is
observed in the absence of an applied stress.

Author Manuscript

GSH and cancer—Increased glutathione synthesis and the resulting lower levels of
reactive oxygen species (ROS) have been suggested to confer a growth advantage to cancer
cells (Traverso et al., 2013). In several human cancer types, including liver, skin, colorectal,
lung, head and neck, breast, and prostate cancers, GCLC and glutathione levels are increased
relative to normal tissue (Gamcsik et al., 2012). In a study involving human breast tumors,
subpopulations of cancer stem cells were shown to have lower levels of ROS primarily
through increased expression of GCLM and GS (Diehn et al., 2009). Pharmacological
inhibition of glutathione synthesis by L-S,R-buthionine sulfoximine in these cancer stem
cells reduced their ability to form colonies and increased their sensitivity to ionizing
radiation. Similarly, L-S,R-buthionine sulfoximine treatment of MDA-MB231 human breast
carcinoma cells enhanced 2-deoxy-D-glucose–induced cytotoxicity (Andringa et al., 2006).
Experimentally induced reductions of GCLC protein levels and corresponding reductions in
intracellular glutathione sensitized human colon cancer cells to cisplatin (Iida et al., 2001).
Prenatal exposure to benzo[a]pyrene, a polycyclic aromatic hydrocarbon, led to increased
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premature ovarian failure and ovarian tumorigenesis in GCLM null mice relative to controls,
due to their diminished glutathione levels (Lim et al., 2013). This subset of studies
highlights the therapeutic potential of targeting GSH homeostasis in a variety of cancer
types.

Glutathione Salvage
γ-Glutamyltranspeptidase

Author Manuscript

GGT initiates the degradation of extracellular glutathione. There are 7 potential full-length
isoforms of the enzyme but only GGT1 and GGT5 have been validated as active
transeptidases (Heisterkamp et al., 2008). GGT1 is the canonical GGT, found at the surface
of epithelial cells and involved in glutathione salvage, whereas GGT5 appears to be
primarily involved in leukotriene biosynthesis as well as the degradation of select
glutathione conjugates (Carter et al., 1998). GGT is a member of the N-terminal nucleophile
(Ntn) superfamily, which is functionally defined by an autocatalytic cleavage reaction that
generates a new N-terminal residue within the protein (Oinonen and Rouvinen, 2000). This
residue then serves as the nucleophile in the enzyme catalyzed reaction. Considerable detail
is known about this autoprocessing and activation event based on studies of GΓT from
several model organisms (Boanca et al., 2006; Boanca et al., 2007; Castonguay et al., 2003;
Okada et al., 2006, 2007; Suzuki and Kumagai, 2002). Interestingly, organisms that do not
maintain an intracellular pool of glutathione (e.g. H. pylori) express GΓT, suggesting that its
main function is salvage of glutathione to provide a growth advantage (Shibayama et al.,
2007). Recently, the crystal structure of human GGT1 was determined which will aid in
detailed mechanistic and inhibitor design studies (West et al., 2013). A comprehensive
review of GΓT can be found within this volume.
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In response to oxidative stress, glutathione and glutathione conjugates are actively
transported out the cell by multidrug resistance-associated proteins (Bachhawat et al., 2013).
To recover the rapidly exported glutathione and glutathione conjugates, GGT initiates
salvage, cleaving the γ-glutamyl peptide bond to generate cysteinylglycine and transferring
the γ-glutamyl group to another amino acid or peptide. Intriguingly, Meister and co-workers
provided evidence that the γ-glutamyl group could be transferred to cystine, imported into
the cell, and reduced intracellularly to generate γ-glutamylcysteine independently of GCL
(Thompson and Meister, 1975). The cysteinylglycine liberated is proposed to be cleaved by
non-specific dipeptidases and cysteine and glycine imported into the cell. PEPT2, a di- and
tripeptide transporter, has also been demonstrated to contribute to uptake of the intact
cysteinylglycine (Frey et al., 2007).

Author Manuscript

γ-Glutamylcyclotransferase
Imported γ-glutamylpeptides are processed in the cell by GGCT, which cyclizes glutamate,
generating 5-oxoproline and the free amino acid or peptide. Although GGCT was first
purified nearly 40 years ago (Board et al., 1978; Orlowski et al., 1969; Palekar et al., 1974),
the gene encoding this enzyme has only recently been identified (Oakley et al., 2008). It
shares sequence and structural similarity to γ-glutamylamine cyclotransferase, which
degrades γ-glutamyl-ɛ-lysine liberated from proteins covalently crosslinked by
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transglutaminases (Oakley et al., 2010). Furthermore, this enzyme family is broadly
represented in bacteria, plants, and other higher eukaryotes. Initial studies by Meister and
co-workers indicated that GGCT purified from rat liver has relatively broad substrate
specificity, consistent with the relatively non-specific transfer of a γ-glutamyl moiety to
acceptor substrates by GGT. These observations led to the proposal of a GGT/GGCT
pathway for import of amino acids, as a component function of the γ-glutamyl cycle
(Orlowski et al., 1969; Palekar et al., 1974). However, GGCT involvement in amino acid
salvage has not been directly demonstrated using systems in which enzyme expression has
been experimentally altered. Since the substrate specificity of human GGCT has not been
extensively characterized, it remains unclear if the enzyme is involved in amino acid import,
intracellular cleavage of γ-glutamylcysteine (Oakley et al., 2008), or apoptotic signaling
(Masuda et al., 2006).
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Several recent reports have suggested that increased expression of GGCT, initially
designated as C7orf24, may have utility as a tumor marker. Using a proteomics approach,
GGCT was found at higher levels in bladder urothelial carcinoma samples relative to normal
controls. Manipulation of GGCT expression indicated that the enzyme provided a growth
advantage to cancerous cells by an unknown mechanism (Kageyama et al., 2007). In human
osteosarcoma, enzyme levels were considerably higher both in cell lines and primary tumors
(Uejima et al., 2011). Knockdown of GGCT by siRNA resulted in cells with slower cell
growth rates, increased clustering, and reduced invasiveness and motility as measured by
standard in vitro methods, consistent with GGCT being involved in tumor progression
(Uejima et al., 2011). Similarly, reduction of GGCT levels by siRNA inhibited the growth of
human lung squamous cell carcinoma in a mouse model (Hama et al., 2012). GGCT is an
effective diagnostic marker in esophageal squamous cell carcinoma, where higher levels of
expression correlate with a more aggressive phenotype (Takemura et al., 2014).
Unfortunately, the impacts on GSH levels within the cell were not reported in those studies
in which GGCT levels were manipulated. Promoter analysis of GGCT suggests that its
expression is cell-cycle dependent, consistent with a potential role in cancer cell
proliferation (Ohno et al., 2011). In contrast, GGCT was initially characterized as a novel
cytochrome c releasing factor, and overexpression in HeLa cells resulted in apoptosis,
suggesting that GGCT may have alternate metabolic functions in different cell types
(Masuda et al., 2006).
5-Oxoprolinase
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Historically, the primary functions of 5-oxoprolinase (OPLAH) have been associated with
glutathione salvage, with the enzyme catalyzing the ATP-dependent cleavage of 5oxoproline to generate glutamate to complete the pathway (Griffith et al., 1978; Orlowski
and Meister, 1970; Van der Werf et al., 1971). Recently, studies of the γ-glutamyl cycle
suggest that 5-oxoproline levels may reflect nutritional status, particularly with respect to
glycine availability (Friesen et al., 2007). When glycine becomes limiting, increased levels
of 5-oxoproline are observed, stimulating amino acid uptake. This is consistent with the
observation that 5-oxoproline levels increase dramatically in GS deficiency (Dahl et al.,
1997; Wellner et al., 1974). This led to the suggestion that the conversion of γglutamylcysteine to 5-oxoproline and cysteine by GGCT may be the major source of 5-
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oxoproline (Oakley et al., 2008). However, there are examples of patients that present with
5-oxoprolinuria who have normal circulating glutathione concentrations despite increased 5oxoproline levels (Calpena et al., 2013). These levels show glutathione homeostasis is
normal in these patients. Therefore, 5-oxoproline may have additional functions, perhaps as
a glutamate reservoir. In addition, the coordinate regulation of GGCT and OPLAH may
provide another level of control in glutathione biosynthesis.
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OPLAH protein levels and activity have been shown to decrease in some human tumor
tissues, including lung and colon, although the extent and overall pattern are not conclusive
(Chen et al., 1998). The authors suggest that differential expression of OPLAH between
normal and cancerous tissue may be exploited by the use of the cysteine pro-drug, L-2oxothiazolidine-4-carboxylic acid (OTZ). OPLAH can hydrolyze OTZ, and the resulting
product spontaneously decarboxylates to generate cysteine. In this fashion, GSH production
would be bolstered in normal cells relative to cancer cells. However, OPLAH levels are
elevated in ovarian cancer (Chien et al., 2009) and unchanged in colon cancer (Chen et al.,
1998), illustrating potential pitfalls of this general approach. In searching for potential
cancer biomarkers, several groups have identified 5-oxoproline as a biomolecule that is
more abundant in tumor cells, such as nasopharyngeal carcinoma (Tang et al., 2011) and
bladder cancer (Kim et al., 2010). In addition, comparison of genome-wide methylation
status in normal versus colorectal cancer cells revealed as a potential biomarker (Naumov et
al., 2013). A comparable study also identified OPLAH as a potential marker in gastric
cancer (Nanjo et al., 2012). In each of these studies, there was no direct association between
OPLAH and glutathione metabolism reported. Given the diversity of metabolic fates for
glutamate, it is likely that the originally proposed γ-glutamyl cycle is overly simplistic and
comprehensive metabolic labeling studies are needed to examine flux of intermediates
through the proposed cycle.

Precursor Availability
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An often overlooked determinant of cellular glutathione levels is precursor availability.
Glutamate, cysteine, and glycine are amino acids that intersect with major metabolic hubs
that reflect on nitrogen and sulfur metabolism, one-carbon metabolism, and overall energy
levels within the cell (Figure 5). Although cysteine is generally considered the limiting
component of glutathione biosynthesis, glutamate and glycine partitioning can impact
glutathione levels. An emerging trend in tumor cell biology is the concept of metabolic
reprogramming to meet core demands on bioenergetics, biosynthesis, and redox homeostasis
(Cairns et al., 2011). For example, Nrf2 is a well-studied transcriptional regulator
responsible for mounting a response to xenobiotic and oxidative stress (Jaramillo and Zhang,
2013; Sporn and Liby, 2012). In addition to its involvement in the production of detoxifying
enzymes, Nrf2 has recently been shown to participate in metabolic reprogramming,
diverting glucose and glutamine to biosynthetic pathways (Mitsuishi et al., 2012). As
discussed below, Nrf2 promotes purine nucleotide synthesis and glutamine metabolism.
Stimulation of these pathways also provides precursors for increased glutathione synthesis
and reducing equivalents, generated via the pentose phosphate pathway, to maintain GSH
pools.
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Central to the concept of metabolic reprogramming is glutamine bioavailability, as some
cancer cells have been shown to depend heavily on this amino acid for rapid proliferation
and protection against ROS (Daye and Wellen, 2012; DeBerardinis et al., 2007; Le et al.,
2012). Although considered a non-essential amino acid under normal metabolic conditions,
glutamine becomes a conditional essential amino acid, needed for biosynthetic purposes.
Glutamine can serve as a nitrogen donor in the production of amino sugars, nucleotides, and
other amino acids. After donation of the γ-amino group, the remaining glutamate can be
incorporated directly into glutathione or transformed into proline. Alternatively, its α-amino
group can serve as a nitrogen donor via transamination to produce aspartate and alanine
from oxaloacetate and pyruvate respectively, and through more complex biosynthesis
pathways, integrated into threonine, serine, glycine, and cysteine. The residual carbon
skeleton, α-ketoglutarate, can then feed into the citric acid cycle. As such, glutamine/
glutamate availability is directly tied to biosynthesis of key biomolecules.
The complex regulatory network that controls glutamine metabolism shares considerable
overlap with pathways implicated in tumor progression. Glutamine is rapidly taken up in
HeLa (cervical adenocarcinoma) and RT112 (urinary bladder carcinoma) cells by SLC1A5
in a Na+-dependent manner. Accumulated intracellular glutamine drives the uptake of
essential amino acids via SLC7A5/SLC3A2 mediated antiport (Nicklin et al., 2009). The
resulting increase of intracellular leucine levels activates the mTORC1 pathway, and the
increased availability of amino acid precursors stimulates proliferation. In contrast,
mTORC1 signaling does not need to be primed by glutamine uptake in the breast cancer
line, MCF-7, as sufficient levels of glutamine are present (Nicklin et al., 2009).
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c-Myc has been shown to increase SLC1A5 and SLC7A5 mRNA levels and to stimulate
glutaminolysis through suppression of miR-23a/b in human P-493 B lymphoma cells and
PC3 prostate cancer cells (Gao et al., 2009). The resulting increase in mitochondrial
glutaminase expression (GLS1) promoted flux through the tricarboxylic acid cycle (TCA)
and more robust glutathione biosynthesis. siRNA-mediated knockdown of GLS1 in both the
lymphoma and prostate cancer cell lines resulted in reduced ATP levels, diminished
glutathione levels, and increased levels of ROS, firmly establishing glutamine metabolism as
a target of c-Myc and as a potential target for cancer therapeutics.
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Phosphate-activated mitochondrial glutaminase (GLS2) has also been shown to initiate
glutaminolysis to protect against ROS through increased glutathione production (Suzuki et
al., 2010). However, GLS2 has different kinetic constants and tissue distribution relative to
GLS1, and is under the control of p53, a tumor suppressor. In this context, GLS2 is thought
to contribute to tumor suppression as its overexpression inhibits tumor cell growth in cell
culture models and GLS2 expression levels are down in liver tumors. In addition to
stimulating GLS2 expression, p53 also activates TP53-inducible glycolysis and apoptosis
regulator (TIGAR), which stimulates the pentose phosphate pathway, resulting in increased
NADPH levels and, through the action of glutathione reductase, increased GSH/GSSG
ratios. Although induction of GLS1 or GLS2 leads to increased antioxidant capacity as a
result of increases in reduced glutathione levels, the opposing effects of GLS1 and GLS2 in
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tumor progression suggest that the timing of and the flux through glutaminolysis can lead to
tumor promotion or suppression.
Cysteine
As discussed above, studies of GGT1 null mice suggested that one of the primary functions
of glutathione was to serve as a means of conveyance for cysteine from the liver to
peripheral tissue (Lieberman et al., 1996). This assertion is supported by the observation that
the addition of N-acetylcysteine to the diet nearly restored the growth rate of the null
animals. Thus, the GGT1-initiated degradation of glutathione ultimately leads to the
liberation and import of cysteine into the cell. GGT1 expression is upregulated in several
cancer types (Pompella et al., 2007; Strasak et al., 2008), and the prevailing hypothesis is
that the ability to effectively scavenge extracellular glutathione confers a growth advantage
to these metabolically demanding cells (Hanigan et al., 1999).
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Another source of cysteine for glutathione biosynthesis originates from methionine (Lu and
Mato, 2012). Methionine adenosyltransferase catalyzes the formation of Sadenosylmethionine (AdoMet, SAM) from methionine and ATP. AdoMet serves as a potent
methyl donor in hundreds of biologically significant reactions with concomitant production
of S-adenosylhomocysteine. Hydrolysis of S-adenosylhomocysteine produces
homoscysteine that can be converted to methionine by either methionine synthase, using 5methyltetrahydrofolate as a methyl donor, or betaine homocysteine methyltransferase, which
requires the choline metabolite, betaine. Alternatively, homoscysteine can be partitioned into
the transsulfuration pathway in which two PLP-dependent enzymes, cystathionine βsynthase and cystathionine γ-lyase, catalyze the condensation of homocysteine and serine to
produce cystathionine, and its subsequent cleavage to α-ketobutyrate and cysteine.

Author Manuscript

A significant fraction of cysteine for glutathione biosynthesis can be produced via the
transsulfuration pathway. For example, approximately half of the cysteine used for
glutathione biosynthesis in HepG2 cells is acquired through the transsulfuration pathway
(Mosharov et al., 2000). In contrast to the conclusions drawn from the studies of GGT1 null
mice, targeted disruption of GCLC in hepatocytes did not lead to dramatic reductions in
cysteine or glutathione levels in extrahepatic tissue (Chen et al., 2007). This suggests that
tissues can derive significant amounts of cysteine from methionine, and are not solely
dependent on salvage of cysteine from circulating glutathione.
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Cystine import has recently emerged as an important process in maintaining intracellular
cysteine levels. System xc− is a cysteine/glutamate antiporter composed of two subunits,
xCT and 4F2 heavy chain. xCT null mice have higher plasma levels of cysteine and lower
circulating levels of glutathione (Sato et al., 2005). Although not required for normal
development, xCT is important in maintaining plasma redox balance, and there is
considerable evidence that cystine is vital for cancer cell survival. Chronic lymphocytic
leukaemia cells do not efficiently uptake cystine and require co-culture with bone-marrowderived stromal cells to maintain cellular glutathione levels (Zhang et al., 2012). The stromal
cells have high levels of system xc− and rapidly assimilate cystine, which is reduced
intracellularly and secreted back into the microenvironment. The chronic lymphocytic
leukaemia cells use the secreted cysteine for glutathione production and improved resistance
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to oxidative stress. Cancer stem cells have elevated levels of CD44 variants that have been
shown to stabilize xCT, increasing cystine import and leading to increased intracellular
glutathione levels (Ishimoto et al., 2011). In addition, Nrf2 signaling stimulates the
expression of xCT to help combat increasing levels of oxidative stress (Sasaki et al., 2002).
Glycine
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Glycine represents another critical biomolecule that connects glutathione to other metabolic
processes (Locasale, 2013). Metabolic profiling studies have demonstrated that significant
amounts of 3-phosphoglycerate are diverted from glycolysis into serine and ultimately
glycine biosynthesis in cultured cancer cell lines (Jain et al., 2012). Phosphoglycerate
dehydrogenase, which catalyzes the committed step in this biosynthetic pathway, has been
found to be upregulated in many human cancer samples (Locasale et al., 2011). Additional
studies have shown that glycine is used for the biosynthesis of purines in rapidly dividing
cancer cells and may potentially serve as a one-carbon donor for downstream methylation
events. In these studies, a significant fraction of exogenously added glycine was
incorporated into glutathione. Overall, it was estimated that approximately two thirds of the
total intracellular glycine arose from biosynthesis and the remainder from exogenous
sources (Jain et al., 2012). The partitioning of glycine into its various metabolic fates allows
cancer cells to control proliferation rates and increases capacity to combat oxidative stress.

Remaining questions and emerging pathways
5-Oxoproline
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Although there have been a number of correlative and observational studies that indicate
dynamic variations in 5-oxoproline levels, the precise cellular functions of 5-oxoproline
beyond GSH salvage remain unclear. The concentrations in normal human plasma and
various tissues are between 20 and 50 μM (Van Der Werf et al., 1975), but can reach several
millimolar in pathological conditions, leading to anion gap metabolic acidosis and ataxia
(Ristoff and Larsson, 2007). Several studies have suggested that 5-oxoproline levels indicate
the availability of glycine and/or cysteine (Metges et al., 2000). In normal individuals
consuming a low protein diet, elevated 5-oxoproline levels were reduced with increased
protein content or supplementation with other sources of nitrogen, such as urea (Jackson et
al., 1996). When cysteine is limiting, the γ-glutamylphosphate intermediate of GCL can
spontaneously cyclize to form 5-oxoproline (Orlowski and Meister, 1971). Increased urinary
excretion of 5-oxoproline has been noted in children gaining weight rapidly during recovery
from severe malnutrition. Glycine supplementation restored 5-oxoproline to normal levels,
suggesting that excess γ-glutamylcysteine was being converted to 5-oxoproline and cysteine
(Meakins et al., 1998; Persaud et al., 1996). Similarly, a study of pregnant women and their
newborn infants has shown an inverse correlation between 5-oxoproline and
dimethylglycine, a glycine precursor (Friesen et al., 2007). Given the number of nutritional
states that lead to increased 5-oxoproline production, it is surprising that OPLAH is not
more effective in hydrolyzing this metabolite.
5-oxoprolinuria has been shown to be associated with urea cycle defects, such as ornithine
transcarbamylase deficiency and carbamoyl phosphate synthetase deficiency (Mayatepek,
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1999). Nephropathic cystinosis mimics the effects of cysteine deficiency and results from a
genetic defect in the lysosomal cystine transporter, which leads to a high level of cystine
accumulation in the lysosome with corresponding low levels of cysteine in the cytosol
(Kumar and Bachhawat, 2010). Similarly, defects in cystathionine synthase, which converts
homocysteine to cysteine, leads to elevated 5-oxoproline levels as well. Homocysteine can
replace cysteine as a substrate for GCL, forming γ-glutamylhomocysteine. However, this
dipeptide is not tolerated by GS, and is efficiently processed by GGCT to generate 5oxoproline and homocysteine (Stokke et al., 1982). Perhaps 5-oxoproline can serve as a
signaling molecule to alter metabolism and limit flux through unproductive metabolic
pathways.

Author Manuscript

As with GGT1, OPLAH is a highly conserved enzyme across diverse species. For example,
human and Methanosarcina acetivorans 5-oxoprolinase share ~45% sequence identity over
the length of this nearly 1300 amino acid protein. This striking conservation is more
remarkable considering that M. acetivorans do not appear to synthesize glutathione or have
close homologues of either GGT or GGCT, suggesting that the enzyme may have additional
enzymatic activities. Eukaryotic 5-oxoprolinases are homodimeric enzymes with two
hydantoinase domains (HyuA and HyuB) per subunit. Hydantoinases can act on a number of
5- and 6-membered ring substrates, perhaps indicating that OPLAH may hydrolyze other
substrates besides 5-oxoproline. Studies on the enzymatic properties of OPLAH have been
relatively limited, and a large range of kinetic constants has been observed (Kumar and
Bachhawat, 2010; Ohkama-Ohtsu et al., 2008; Williamson and Meister, 1982). The enzyme
appears to require both monovalent and divalent cations to maintain catalytic activity and is
stabilized by the presence of 5-oxoproline. Oxidation of the protein leads to inactivation
(Van der Werf et al., 1971; Watanabe et al., 2004). A large-scale study by Ischiropoulos et
al. reported that 5-oxoprolinase in mouse kidney, liver, and lung is S-nitrosylated (Doulias et
al., 2013). The impacts of nitrosylation on the enzyme activity and stability have yet to be
elucidated, but it is possible that some of the 24 cysteine residues found in human OPLAH
may be sites of post-translational regulation. Addition studies are warranted to define the
breadth of reactions catalyzed by OPLAH.
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ChaC1
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An exciting development has been the identification of a cytosolic pathway for the
degradation of glutathione (Kumar et al., 2012). Human ChaC1 has the ability to cleave the
γ-glutamyl group from glutathione specifically, as the enzyme had minimal activity with γglutamyl dipeptide substrates. The observed kinetic constants suggest ChaC1 activity is
physiologically relevant, as the measured Km for glutathione was approximately 3 mM.
Homology modeling of human ChaC1 indicated that the enzyme adopts a fold similar to
GΓXT, despite low sequence identity. The validity of the model was confirmed by
mutational analysis of ChaC1, in which a structurally conserved glutamate, Glu 116, was
demonstrated to be critical for catalysis. In an organic sulphur auxotroph strain of
S.cerevisiae, ChaC1 expression conferred the ability to grow on glutathione as the sole
sulfur source. Its ability to initiate glutathione degradation is consistent with the recent
observation that amino acid starvation induced by bacterial pathogens leads to dramatic
upregulation of ChaC1 expression (Tattoli et al., 2012).
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ChaC1 was initially identified as part of the Unfolded Protein Response (UPR) cascade,
downstream of ATF4 (Mungrue et al., 2009). Overexpression of ChaC1 led to apoptosis
whereas knockdown by siRNA attenuated apoptosis in HEK293 cells, consistent with its
involvement in the UPR. Its ability to cleave the γ-glutamyl peptide bond of glutathione
likely facilitates apoptosis, as lower GSH levels are a hallmark of this process. Similarly, in
head and neck squamous cell carcinoma cells overexpression of ChaC1 resulted in slower
proliferation rates and induced apoptosis (Joo et al., 2012). In contrast, neither
overexpression nor reduction of ChaC1 protein levels impacted apoptosis in breast cancer
and ovarian cancer lines. siRNA mediated knockdown of ChaC1 resulted in reduced
migration and proliferation, whereas overexpression of ChaC1 increased migration and
proliferation (Goebel et al., 2012). An analysis of human breast and ovarian tumors
indicated that higher ChaC1 levels correlated with more advanced stage and poorer
prognosis.
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Overall, these studies highlight our limited understanding of ChaC1 function. Tumor cells
generally tend to have higher levels of ROS and require elevated glutathione levels for
survival. However, initial observations indicated that ChaC1 participated in apoptosis and
GSH degradation. Therefore, it is surprising that breast and ovarian tumors would have
higher ChaC1 levels. Perhaps variants of ChaC1 have alternate functions. There is some
ambiguity as to the proper start site for translation of human ChaC1, as there is another
potential initiator methionine that would result in a protein that is shorter by 43 amino acid
residues. In addition, there are two isoforms of the enzyme, with variant 2 resulting in a 45
amino acid deletion near the center of the coding region. It is unclear how each of these
changes would impact ChaC1 function and perhaps isoform distributions of ChaC1 may be
an important consideration (Goebel et al., 2012). Currently only the standard ChaC1 isoform
(Kumar et al., 2012) has been characterized in vitro and further studies are clearly needed.
Additional functions of γ-glutamylcysteine and glutathione
The contributions of γ-glutamylcysteine and glutathione to cellular function have been
expanded in two recent studies. Mitochondrial γ-glutamylcysteine was shown to be
sufficient to respond to oxidative stress irrespective of the cytsolic glutathione concentration
(Quintana-Cabrera and Bolanos, 2013). Specifically, γ-glutamylcysteine was shown to be an
enzymatic cofactor for glutathione peroxidase 1 (GPX1), and this system was able to control
mitochondrial H2O2 concentrations to limit cellular damage. However, it is unclear how γglutamylcysteine is partitioned between detoxification and glutathione synthesis pathways
and how oxidized γ-glutamylcysteine is reduced, as this process is not likely to be mediated
by glutathione reductase.
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Glutathione has been shown to participate in a futile cycle that depletes NADPH, leading to
oxidative stress (Sullivan et al., 2013). Patients with hereditary leiomyomatosis and renal
cell carcinoma (HLRCC) have reduced fumarate hydratase (fumarase) activity. As flux
through the citric acid cycle is compromised, cells can accumulate fumarate, which serves as
a proto-oncometabolite. Reduced glutathione adds across the double bond of fumarate to
generate succinated glutathione. This recently identified metabolite is a substrate of
glutathione reductase, which can regenerate reduced glutathione at the expense of NADPH.
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As a result, the NADPH ratio drops concomitant with an increase in oxidative stress, leading
to stabilization of HIF1α. Identifying the potential contributions of succinated glutathione to
disease progression in other tissue types is an exciting area of future research.

Summary
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Glutathione is a critical detoxification precursor and a vital component of redox homeostasis
thought to be especially beneficial in promoting growth and survival of tumor cells. Though
the enzymes of the γ-glutamyl cycle have been studied over a period of several decades, new
complexities have arisen through the characterization of genetically engineered mouse
models that perturb glutathione levels without directly impacting disease progression.
Further advances in technologies such as mass spectrometry have improved detection limits
for relevant metabolites, and revealed points of regulated flux through glutathione synthesis
and salvage pathways that intersect with other central metabolic pathways also subject to
reprogramming in cancer. However, as these innovations have answered mechanistic
questions about the roles of glutathione in cancer, new questions have come to the forefront.
For example, increases in steady state glutathione within bloodborne and peripheral solid
tumors are not accompanied consistently by upregulation of the biosynthetic or salvage
enzymes, and liver tumors have actually shown reduced glutathione, despite the pivotal
importance of glutathione to the metabolism of this tissue in general. To resolve these
questions, it will be necessary to focus attention on the structural and functional regulation
of the γ-glutamyl cycle enzymes and systematically assess glutathione with respect to each
perturbation. It is also increasingly evident that the pathways of central metabolism that are
altered to increase general biosynthetic potential in cancer (e.g.; serine and glycine
metabolism, pentose phosphate pathway) are intimately related to glutathione levels. It is
tempting to speculate that as tumor cells reprogram metabolism in response to
microenvironment conditions, there may be co-evolution of γ-glutamyl cycle enzyme
adaptations that optimally select with, or reciprocally to, the other central metabolic
pathways. Detailed examination of metabolite flux in conjunction with the cross-talking
pathways will be important to dissect these mechanisms and further understand the role of
glutathione.

Acknowledgments
This work was made possible by National Institutes of Health Grants R01 GM077289 (J.J.B.), R01 CA165574
(M.A.S.), and P20 RR-17675 (National Center for Research Resources).

References
Author Manuscript

Andringa KK, Coleman MC, Aykin-Burns N, Hitchler MJ, Walsh SA, Domann FE, Spitz DR.
Inhibition of glutamate cysteine ligase activity sensitizes human breast cancer cells to the toxicity of
2-deoxy-D-glucose. Cancer Res. 2006; 66:1605–1610. [PubMed: 16452219]
Bachhawat AK, Thakur A, Kaur J, Zulkifli M. Glutathione transporters. Biochim Biophys Acta. 2013;
1830:3154–3164. [PubMed: 23206830]
Backos DS, Fritz KS, McArthur DG, Kepa JK, Donson AM, Petersen DR, Foreman NK, Franklin CC,
Reigan P. Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on
chemoresistance in glioblastoma. Neurochemical research. 2013; 38:1838–1849. [PubMed:
23743623]

Adv Cancer Res. Author manuscript; available in PMC 2015 July 27.

Liu et al.

Page 17

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Backos DS, Fritz KS, Roede JR, Petersen DR, Franklin CC. Posttranslational modification and
regulation of glutamate-cysteine ligase by the alpha,beta-unsaturated aldehyde 4-hydroxy-2nonenal. Free Radic Biol Med. 2011; 50:14–26. [PubMed: 20970495]
Biterova EI, Barycki JJ. Mechanistic details of glutathione biosynthesis revealed by crystal structures
of Saccharomyces cerevisiae glutamate cysteine ligase. The Journal of biological chemistry. 2009;
284:32700–32708. [PubMed: 19726687]
Boanca G, Sand A, Barycki JJ. Uncoupling the enzymatic and autoprocessing activities of
Helicobacter pylori gamma-glutamyltranspeptidase. The Journal of biological chemistry. 2006;
281:19029–19037. [PubMed: 16672227]
Boanca G, Sand A, Okada T, Suzuki H, Kumagai H, Fukuyama K, Barycki JJ. Autoprocessing of
Helicobacter pylori gamma-glutamyltranspeptidase leads to the formation of a threonine-threonine
catalytic dyad. The Journal of biological chemistry. 2007; 282:534–541. [PubMed: 17107958]
Board PG, Moore KA, Smith JE. Purification and properties of gamma-glutamylcyclotransferase from
human erythrocytes. The Biochemical journal. 1978; 173:427–431. [PubMed: 29601]
Brigelius-Flohe R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta. 2013; 1830:3289–
3303. [PubMed: 23201771]
Brown TR, Drummond ML, Barelier S, Crutchfield AS, Dinescu A, Slavens KD, Cundari TR,
Anderson ME. Aspartate 458 of human glutathione synthetase is important for cooperativity and
active site structure. Biochem Biophys Res Commun. 2011; 411:536–542. [PubMed: 21771585]
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nature reviews Cancer. 2011;
11:85–95. [PubMed: 21258394]
Calpena E, Casado M, Martinez-Rubio D, Nascimento A, Colomer J, Gargallo E, Garcia-Cazorla A,
Palau F, Artuch R, Espinos C. 5-Oxoprolinuria in Heterozygous Patients for 5-Oxoprolinase
(OPLAH) Missense Changes. JIMD reports. 2013; 7:123–128. [PubMed: 23430506]
Carter BZ, Shi ZZ, Barrios R, Lieberman MW. gamma-glutamyl leukotrienase, a gamma-glutamyl
transpeptidase gene family member, is expressed primarily in spleen. J Biol Chem. 1998;
273:28277–28285. [PubMed: 9774450]
Castonguay R, Lherbet C, Keillor JW. Kinetic studies of rat kidney gamma-glutamyltranspeptidase
deacylation reveal a general base-catalyzed mechanism. Biochemistry. 2003; 42:11504–11513.
[PubMed: 14516202]
Chen X, Schecter RL, Griffith OW, Hayward MA, Alpert LC, Batist G. Characterization of 5-oxo-Lprolinase in normal and tumor tissues of humans and rats: a potential new target for biochemical
modulation of glutathione. Clin Cancer Res. 1998; 4:131–138. [PubMed: 9516961]
Chen Y, Shertzer HG, Schneider SN, Nebert DW, Dalton TP. Glutamate cysteine ligase catalysis:
dependence on ATP and modifier subunit for regulation of tissue glutathione levels. J Biol Chem.
2005; 280:33766–33774. [PubMed: 16081425]
Chen Y, Yang Y, Miller ML, Shen D, Shertzer HG, Stringer KF, Wang B, Schneider SN, Nebert DW,
Dalton TP. Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial
injury and liver failure. Hepatology. 2007; 45:1118–1128. [PubMed: 17464988]
Chien J, Fan JB, Bell DA, April C, Klotzle B, Ota T, Lingle WL, Gonzalez Bosquet J, Shridhar V,
Hartmann LC. Analysis of gene expression in stage I serous tumors identifies critical pathways
altered in ovarian cancer. Gynecologic oncology. 2009; 114:3–11. [PubMed: 19410283]
Currais A, Maher P. Functional consequences of age-dependent changes in glutathione status in the
brain. Antioxid Redox Signal. 2013; 19:813–822. [PubMed: 23249101]
Dahl N, Pigg M, Ristoff E, Gali R, Carlsson B, Mannervik B, Larsson A, Board P. Missense mutations
in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria,
hemolytic anemia and neurological dysfunction. Human molecular genetics. 1997; 6:1147–1152.
[PubMed: 9215686]
Dalton TP, Dieter MZ, Yang Y, Shertzer HG, Nebert DW. Knockout of the mouse glutamate cysteine
ligase catalytic subunit (Gclc) gene: embryonic lethal when homozygous, and proposed model for
moderate glutathione deficiency when heterozygous. Biochem Biophys Res Commun. 2000;
279:324–329. [PubMed: 11118286]

Adv Cancer Res. Author manuscript; available in PMC 2015 July 27.

Liu et al.

Page 18

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in
tumorigenesis. Seminars in cell & developmental biology. 2012; 23:362–369. [PubMed:
22349059]
DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond
aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the
requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007; 104:19345–
19350. [PubMed: 18032601]
Dickinson DA, Forman HJ. Glutathione in defense and signaling: lessons from a small thiol. Ann N Y
Acad Sci. 2002; 973:488–504. [PubMed: 12485918]
Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M,
Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK,
Quake SR, Brown JM, Weissman IL, Clarke MF. Association of reactive oxygen species levels
and radioresistance in cancer stem cells. Nature. 2009; 458:780–783. [PubMed: 19194462]
Dinescu A, Brown TR, Barelier S, Cundari TR, Anderson ME. The role of the glycine triad in human
glutathione synthetase. Biochem Biophys Res Commun. 2010; 400:511–516. [PubMed:
20800579]
Dinescu A, Cundari TR, Bhansali VS, Luo JL, Anderson ME. Function of conserved residues of
human glutathione synthetase: implications for the ATP-grasp enzymes. J Biol Chem. 2004;
279:22412–22421. [PubMed: 14990577]
Doulias PT, Tenopoulou M, Greene JL, Raju K, Ischiropoulos H. Nitric oxide regulates mitochondrial
fatty acid metabolism through reversible protein S-nitrosylation. Science signaling. 2013; 6:rs1.
[PubMed: 23281369]
Fan X, Liu X, Hao S, Wang B, Robinson ML, Monnier VM. The LEGSKO mouse: a mouse model of
age-related nuclear cataract based on genetic suppression of lens glutathione synthesis. PloS one.
2012; 7:e50832. [PubMed: 23226398]
Fawaz MV, Topper ME, Firestine SM. The ATP-grasp enzymes. Bioorganic chemistry. 2011; 39:185–
191. [PubMed: 21920581]
Franklin CC, Backos DS, Mohar I, White CC, Forman HJ, Kavanagh TJ. Structure, function, and posttranslational regulation of the catalytic and modifier subunits of glutamate cysteine ligase. Mol
Aspects Med. 2009; 30:86–98. [PubMed: 18812186]
Franklin CC, Krejsa CM, Pierce RH, White CC, Fausto N, Kavanagh TJ. Caspase-3-Dependent
Cleavage of the Glutamate-L-Cysteine Ligase Catalytic Subunit during Apoptotic Cell Death. Am
J Pathol. 2002; 160:1887–1894. [PubMed: 12000740]
Fraser JA, Kansagra P, Kotecki C, Saunders RD, McLellan LI. The modifier subunit of Drosophila
glutamate-cysteine ligase regulates catalytic activity by covalent and noncovalent interactions and
influences glutathione homeostasis in vivo. J Biol Chem. 2003; 278:46369–46377. [PubMed:
12954617]
Frey IM, Rubio-Aliaga I, Siewert A, Sailer D, Drobyshev A, Beckers J, de Angelis MH, Aubert J, Bar
Hen A, Fiehn O, Eichinger HM, Daniel H. Profiling at mRNA, protein, and metabolite levels
reveals alterations in renal amino acid handling and glutathione metabolism in kidney tissue of
Pept2−/− mice. Physiological genomics. 2007; 28:301–310. [PubMed: 17077276]
Friesen RW, Novak EM, Hasman D, Innis SM. Relationship of dimethylglycine, choline, and betaine
with oxoproline in plasma of pregnant women and their newborn infants. J Nutr. 2007; 137:2641–
2646. [PubMed: 18029477]
Gamcsik MP, Kasibhatla MS, Teeter SD, Colvin OM. Glutathione levels in human tumors.
Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2012;
17:671–691.
Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE,
Mendell JT, Dang CV. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase
expression and glutamine metabolism. Nature. 2009; 458:762–765. [PubMed: 19219026]
Goebel G, Berger R, Strasak AM, Egle D, Muller-Holzner E, Schmidt S, Rainer J, Presul E, Parson W,
Lang S, Jones A, Widschwendter M, Fiegl H. Elevated mRNA expression of CHAC1 splicing
variants is associated with poor outcome for breast and ovarian cancer patients. British journal of
cancer. 2012; 106:189–198. [PubMed: 22108517]

Adv Cancer Res. Author manuscript; available in PMC 2015 July 27.

Liu et al.

Page 19

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Gogos A, Shapiro L. Large conformational changes in the catalytic cycle of glutathione synthase.
Structure. 2002; 10:1669–1676. [PubMed: 12467574]
Griffith OW, Bridges RJ, Meister A. Evidence that the gamma-glutamyl cycle functions in vivo using
intracellular glutathione: effects of amino acids and selective inhibition of enzymes. Proc Natl
Acad Sci U S A. 1978; 75:5405–5408. [PubMed: 31622]
Griffith OW, Mulcahy RT. The enzymes of glutathione synthesis: gamma-glutamylcysteine
synthetase. Adv Enzymol Relat Areas Mol Biol. 1999; 73:209–267. xii. [PubMed: 10218110]
Hama S, Arata M, Nakamura I, Kasetani T, Itakura S, Tsuchiya H, Yoshiki T, Kogure K. Prevention
of tumor growth by needle-free jet injection of anti-C7orf24 siRNA. Cancer Gene Ther. 2012;
19:553–557. [PubMed: 22653386]
Hanigan MH, Gallagher BC, Townsend DM, Gabarra V. Gamma-glutamyl transpeptidase accelerates
tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis. 1999;
20:553–559. [PubMed: 10223181]
Hanigan MH, Ricketts WA. Extracellular glutathione is a source of cysteine for cells that express
gamma-glutamyl transpeptidase. Biochemistry. 1993; 32:6302–6306. [PubMed: 8099811]
Harding JJ. Free and protein-bound glutathione in normal and cataractous human lenses. Biochem J.
1970; 117:957–960. [PubMed: 5451916]
Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;
45:51–88. [PubMed: 15822171]
Heisterkamp N, Groffen J, Warburton D, Sneddon TP. The human gamma-glutamyltransferase gene
family. Human genetics. 2008; 123:321–332. [PubMed: 18357469]
Huang CS, Chang LS, Anderson ME, Meister A. Catalytic and regulatory properties of the heavy
subunit of rat kidney gamma-glutamylcysteine synthetase. J Biol Chem. 1993; 268:19675–19680.
[PubMed: 8103521]
Iida T, Kijima H, Urata Y, Goto S, Ihara Y, Oka M, Kohno S, Scanlon KJ, Kondo T. Hammerhead
ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to
cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug
resistance proteins. Cancer Gene Ther. 2001; 8:803–814. [PubMed: 11687904]
Ikeda Y, Taniguchi N. Gene expression of gamma-glutamyltranspeptidase. Methods Enzymol. 2005;
401:408–425. [PubMed: 16399400]
Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R,
Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M,
Suematsu M, Baba H, Saya H. CD44 variant regulates redox status in cancer cells by stabilizing
the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer cell. 2011; 19:387–
400. [PubMed: 21397861]
Jackson AA, Persaud C, Meakins TS, Bundy R. Urinary excretion of 5-L-oxoproline (pyroglutamic
acid) is increased in normal adults consuming vegetarian or low protein diets. J Nutr. 1996;
126:2813–2822. [PubMed: 8914953]
Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish
CB, Mootha VK. Metabolite profiling identifies a key role for glycine in rapid cancer cell
proliferation. Science. 2012; 336:1040–1044. [PubMed: 22628656]
Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes
Dev. 2013; 27:2179–2191. [PubMed: 24142871]
Joo NE, Ritchie K, Kamarajan P, Miao D, Kapila YL. Nisin, an apoptogenic bacteriocin and food
preservative, attenuates HNSCC tumorigenesis via CHAC1. Cancer medicine. 2012; 1:295–305.
[PubMed: 23342279]
Kageyama S, Iwaki H, Inoue H, Isono T, Yuasa T, Nogawa M, Maekawa T, Ueda M, Kajita Y, Ogawa
O, Toguchida J, Yoshiki T. A novel tumor-related protein, C7orf24, identified by proteome
differential display of bladder urothelial carcinoma. Proteomics Clin Appl. 2007; 1:192–199.
[PubMed: 21136669]
Keillor JW, Castonguay R, Lherbet C. Gamma-glutamyl transpeptidase substrate specificity and
catalytic mechanism. Methods Enzymol. 2005; 401:449–467. [PubMed: 16399402]
Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server.
Nat Protoc. 2009; 4:363–371. [PubMed: 19247286]

Adv Cancer Res. Author manuscript; available in PMC 2015 July 27.

Liu et al.

Page 20

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Kim JW, Lee G, Moon SM, Park MJ, Hong SK, Ahn YH, Kim KR, Paik MJ. Metabolomic screening
and star pattern recognition by urinary amino acid profile analysis from bladder cancer patients.
Metabolomics. 2010; 6:202–206.
Kinlough CL, Poland PA, Bruns JB, Hughey RP. Gamma-glutamyltranspeptidase: disulfide bridges,
propeptide cleavage, and activation in the endoplasmic reticulum. Methods Enzymol. 2005;
401:426–449. [PubMed: 16399401]
Krejsa CM, Franklin CC, White CC, Ledbetter JA, Schieven GL, Kavanagh TJ. Rapid activation of
glutamate cysteine ligase following oxidative stress. J Biol Chem. 2010; 285:16116–16124.
[PubMed: 20332089]
Kumar A, Bachhawat AK. OXP1/YKL215c encodes an ATP-dependent 5-oxoprolinase in
Saccharomyces cerevisiae: functional characterization, domain structure and identification of
actin-like ATP-binding motifs in eukaryotic 5-oxoprolinases. FEMS yeast research. 2010; 10:394–
401. [PubMed: 20402795]
Kumar A, Tikoo S, Maity S, Sengupta S, Sengupta S, Kaur A, Bachhawat AK. Mammalian
proapoptotic factor ChaC1 and its homologues function as gamma-glutamyl cyclotransferases
acting specifically on glutathione. EMBO Rep. 2012; 13:1095–1101. [PubMed: 23070364]
Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene
C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4.
Proc Natl Acad Sci U S A. 1994; 91:7663–7667. [PubMed: 8052639]
Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H,
Zimmerman LJ, Liebler DC, Slebos RJ, Lorkiewicz PK, Higashi RM, Fan TW, Dang CV.
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B
cells. Cell metabolism. 2012; 15:110–121. [PubMed: 22225880]
Lieberman MW, Wiseman AL, Shi ZZ, Carter BZ, Barrios R, Ou CN, Chevez-Barrios P, Wang Y,
Habib GM, Goodman JC, Huang SL, Lebovitz RM, Matzuk MM. Growth retardation and cysteine
deficiency in gamma-glutamyl transpeptidase-deficient mice. Proc Natl Acad Sci U S A. 1996;
93:7923–7926. [PubMed: 8755578]
Lillig CH, Berndt C, Holmgren A. Glutaredoxin systems. Biochim Biophys Acta. 2008; 1780:1304–
1317. [PubMed: 18621099]
Lim J, Lawson GW, Nakamura BN, Ortiz L, Hur JA, Kavanagh TJ, Luderer U. Glutathione-deficient
mice have increased sensitivity to transplacental benzo[a]pyrene-induced premature ovarian
failure and ovarian tumorigenesis. Cancer Res. 2013; 73:908–917. [PubMed: 23135907]
Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nature reviews.
Cancer. 2013; 13:572–583. [PubMed: 23822983]
Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM,
Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R,
Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM,
Brugge JS, Cantley LC, Vander Heiden MG. Phosphoglycerate dehydrogenase diverts glycolytic
flux and contributes to oncogenesis. Nat Genet. 2011; 43:869–874. [PubMed: 21804546]
Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009; 30:42–59. [PubMed: 18601945]
Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013; 1830:3143–3153. [PubMed: 22995213]
Lu SC, Kuhlenkamp J, Garcia-Ruiz C, Kaplowitz N. Hormone-mediated down-regulation of hepatic
glutathione synthesis in the rat. J Clin Invest. 1991; 88:260–269. [PubMed: 1647417]
Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiological reviews.
2012; 92:1515–1542. [PubMed: 23073625]
Luo JL, Huang CS, Babaoglu K, Anderson ME. Novel kinetics of mammalian glutathione synthetase:
characterization of gamma-glutamyl substrate cooperative binding. Biochem Biophys Res
Commun. 2000; 275:577–581. [PubMed: 10964706]
Mannervik B. Five decades with glutathione and the GSTome. J Biol Chem. 2012; 287:6072–6083.
[PubMed: 22247548]
Masuda Y, Maeda S, Watanabe A, Sano Y, Aiuchi T, Nakajo S, Itabe H, Nakaya K. A novel 21-kDa
cytochrome c-releasing factor is generated upon treatment of human leukemia U937 cells with
geranylgeraniol. Biochem Biophys Res Commun. 2006; 346:454–460. [PubMed: 16765912]

Adv Cancer Res. Author manuscript; available in PMC 2015 July 27.

Liu et al.

Page 21

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Mayatepek E. 5-Oxoprolinuria in patients with and without defects in the gamma-glutamyl cycle. Eur J
Pediatr. 1999; 158:221–225. [PubMed: 10094443]
Meakins TS, Persaud C, Jackson AA. Dietary supplementation with L-methionine impairs the
utilization of urea-nitrogen and increases 5-L-oxoprolinuria in normal women consuming a low
protein diet. J Nutr. 1998; 128:720–727. [PubMed: 9521634]
Meister A. On the enzymology of amino acid transport. Science. 1973; 180:33–39. [PubMed:
4144403]
Meister A. The gamma-glutamyl cycle. Diseases associated with specific enzyme deficiencies. Ann
Intern Med. 1974; 81:247–253. [PubMed: 4152527]
Meister A, Anderson ME. Glutathione. Annual review of biochemistry. 1983; 52:711–760.
Metges CC, Yu YM, Cai W, Lu XM, Wong S, Regan MM, Ajami A, Young VR. Oxoproline kinetics
and oxoproline urinary excretion during glycine- or sulfur amino acid-free diets in humans. Am J
Physiol Endocrinol Metab. 2000; 278:E868–876. [PubMed: 10780943]
Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H.
Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer
cell. 2012; 22:66–79. [PubMed: 22789539]
Mosharov E, Cranford MR, Banerjee R. The quantitatively important relationship between
homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its
regulation by redox changes. Biochemistry. 2000; 39:13005–13011. [PubMed: 11041866]
Mungrue IN, Pagnon J, Kohannim O, Gargalovic PS, Lusis AJ. CHAC1/MGC4504 is a novel
proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP
cascade. J Immunol. 2009; 182:466–476. [PubMed: 19109178]
Nanjo S, Asada K, Yamashita S, Nakajima T, Nakazawa K, Maekita T, Ichinose M, Sugiyama T,
Ushijima T. Identification of gastric cancer risk markers that are informative in individuals with
past H. pylori infection. Gastric cancer: official journal of the International Gastric Cancer
Association and the Japanese Gastric Cancer Association. 2012; 15:382–388.
Naumov VA, Generozov EV, Zaharjevskaya NB, Matushkina DS, Larin AK, Chernyshov SV,
Alekseev MV, Shelygin YA, Govorun VM. Genome-scale analysis of DNA methylation in
colorectal cancer using Infinium HumanMethylation450 BeadChips. Epigenetics: official journal
of the DNA Methylation Society. 2013; 8:921–934. [PubMed: 23867710]
Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C,
Wilson C, Myer VE, MacKeigan JP, Porter JA, Wang YK, Cantley LC, Finan PM, Murphy LO.
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009; 136:521–534.
[PubMed: 19203585]
Oakley AJ, Coggan M, Board PG. Identification and characterization of gamma-glutamylamine
cyclotransferase, an enzyme responsible for gamma-glutamyl-epsilon-lysine catabolism. The
Journal of biological chemistry. 2010; 285:9642–9648. [PubMed: 20110353]
Oakley AJ, Yamada T, Liu D, Coggan M, Clark AG, Board PG. The identification and structural
characterization of C7orf24 as gamma-glutamyl cyclotransferase. An essential enzyme in the
gamma-glutamyl cycle. The Journal of biological chemistry. 2008; 283:22031–22042. [PubMed:
18515354]
Ochi T. Hydrogen peroxide increases the activity of gamma-glutamylcysteine synthetase in cultured
Chinese hamster V79 cells. Arch Toxicol. 1995; 70:96–103. [PubMed: 8773181]
Ochi T. Menadione causes increases in the level of glutathione and in the activity of gammaglutamylcysteine synthetase in cultured Chinese hamster V79 cells. Toxicology. 1996; 112:45–55.
[PubMed: 8792848]
Ohkama-Ohtsu N, Oikawa A, Zhao P, Xiang C, Saito K, Oliver DJ. A gamma-glutamyl
transpeptidase-independent pathway of glutathione catabolism to glutamate via 5-oxoproline in
Arabidopsis. Plant physiology. 2008; 148:1603–1613. [PubMed: 18768907]
Ohno Y, Hattori A, Ueda M, Kageyama S, Yoshiki T, Kakeya H. Multiple NF-Y-binding CCAAT
boxes are essential for transcriptional regulation of the human C7orf24 gene, a novel tumorassociated gene. Febs J. 2011; 278:4088–4099. [PubMed: 21883928]
Oinonen C, Rouvinen J. Structural comparison of Ntn-hydrolases. Protein Sci. 2000; 9:2329–2337.
[PubMed: 11206054]

Adv Cancer Res. Author manuscript; available in PMC 2015 July 27.

Liu et al.

Page 22

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Okada T, Suzuki H, Wada K, Kumagai H, Fukuyama K. Crystal structures of gammaglutamyltranspeptidase from Escherichia coli, a key enzyme in glutathione metabolism, and its
reaction intermediate. Proc Natl Acad Sci U S A. 2006; 103:6471–6476. [PubMed: 16618936]
Okada T, Suzuki H, Wada K, Kumagai H, Fukuyama K. Crystal structure of the gammaglutamyltranspeptidase precursor protein from Escherichia coli - Structural changes autocatalytic
processing and implications for the maturation mechanism. J Biol Chem. 2007; 282:2433–2439.
[PubMed: 17135273]
Orlowski M, Meister A. The gamma-glutamyl cycle: a possible transport system for amino acids. Proc
Natl Acad Sci U S A. 1970; 67:1248–1255. [PubMed: 5274454]
Orlowski M, Meister A. Partial reactions catalyzed by -glutamylcysteine synthetase and evidence for
an activated glutamate intermediate. J Biol Chem. 1971; 246:7095–7105. [PubMed: 4256952]
Orlowski M, Richman PG, Meister A. Isolation and properties of gamma-L-glutamylcyclotransferase
from human brain. Biochemistry. 1969; 8:1048–1055. [PubMed: 5781001]
Palekar AG, Tate SS, Meister A. Formation of 5-oxoproline from glutathione in erythrocytes by the
gamma-glutamyltranspeptidase-cyclotransferase pathway. Proc Natl Acad Sci U S A. 1974;
71:293–297. [PubMed: 4150022]
Persaud C, Forrester T, Jackson AA. Urinary excretion of 5-L-oxoproline (pyroglutamic acid) is
increased during recovery from severe childhood malnutrition and responds to supplemental
glycine. J Nutr. 1996; 126:2823–2830. [PubMed: 8914954]
Pompella A, Corti A, Paolicchi A, Giommarelli C, Zunino F. Gamma-glutamyltransferase, redox
regulation and cancer drug resistance. Current opinion in pharmacology. 2007; 7:360–366.
[PubMed: 17613273]
Quintana-Cabrera R, Bolanos JP. Glutathione and gamma-glutamylcysteine in the antioxidant and
survival functions of mitochondria. Biochemical Society transactions. 2013; 41:106–110.
[PubMed: 23356267]
Richman PG, Meister A. Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric feedback
inhibition by glutathione. J Biol Chem. 1975; 250:1422–1426. [PubMed: 1112810]
Ristoff E, Larsson A. Inborn errors in the metabolism of glutathione. Orphanet journal of rare diseases.
2007; 2:16. [PubMed: 17397529]
Sasaki H, Sato H, Kuriyama-Matsumura K, Sato K, Maebara K, Wang H, Tamba M, Itoh K,
Yamamoto M, Bannai S. Electrophile response element-mediated induction of the cystine/
glutamate exchange transporter gene expression. J Biol Chem. 2002; 277:44765–44771.
[PubMed: 12235164]
Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K,
Moriguchi T, Takahashi S, Bannai S. Redox imbalance in cystine/glutamate transporter-deficient
mice. J Biol Chem. 2005; 280:37423–37429. [PubMed: 16144837]
Seelig GF, Simondsen RP, Meister A. Reversible dissociation of gamma-glutamylcysteine synthetase
into two subunits. J Biol Chem. 1984; 259:9345–9347. [PubMed: 6146611]
Sekura R, Meister A. Glutathione turnover in the kidney; considerations relating to the gammaglutamyl cycle and the transport of amino acids. Proc Natl Acad Sci U S A. 1974; 71:2969–2972.
[PubMed: 4153363]
Shi ZZ, Osei-Frimpong J, Kala G, Kala SV, Barrios RJ, Habib GM, Lukin DJ, Danney CM, Matzuk
MM, Lieberman MW. Glutathione synthesis is essential for mouse development but not for cell
growth in culture. Proc Natl Acad Sci U S A. 2000; 97:5101–5106. [PubMed: 10805773]
Shibayama K, Wachino J, Arakawa Y, Saidijam M, Rutherford NG, Henderson PJF. Metabolism of
glutamine and glutathione via gamma-glutamyltranspeptidase and glutamate transport in
Helicobacter pylori: possible significance in the pathophysiology of the organism. Mol
Microbiol. 2007; 64:396–406. [PubMed: 17381553]
Siitonen T, Alaruikka P, Mantymaa P, Savolainen ER, Kavanagh TJ, Krejsa CM, Franklin CC,
Kinnula V, Koistinen P. Protection of acute myeloblastic leukemia cells against apoptotic cell
death by high glutathione and gamma-glutamylcysteine synthetase levels during etoposideinduced oxidative stress. Annals of oncology: official journal of the European Society for
Medical Oncology/ESMO. 1999; 10:1361–1367. [PubMed: 10631466]

Adv Cancer Res. Author manuscript; available in PMC 2015 July 27.

Liu et al.

Page 23

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Slavens KD, Brown TR, Barakat KA, Cundari TR, Anderson ME. Valine 44 and valine 45 of human
glutathione synthetase are key for subunit stability and negative cooperativity. Biochem Biophys
Res Commun. 2011; 410:597–601. [PubMed: 21683691]
Snoke JE, Bloch K. Studies on the mechanism of action of glutathione synthetase. J Biol Chem. 1955;
213:825–835. [PubMed: 14367343]
Sousa Silva M, Gomes RA, Ferreira AE, Ponces Freire A, Cordeiro C. The glyoxalase pathway: the
first hundred years… and beyond. Biochem J. 2013; 453:1–15. [PubMed: 23763312]
Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nature
reviews. Cancer. 2012; 12:564–571. [PubMed: 22810811]
Stokke O, Marstein S, Jellum E, Lie SO. Accumulation of pyroglutamic acid (5-oxoproline) in
homocystinuria. Scand J Clin Lab Invest. 1982; 42:361–369. [PubMed: 7134819]
Strasak AM, Pfeiffer RM, Klenk J, Hilbe W, Oberaigner W, Gregory M, Concin H, Diem G, Pfeiffer
KP, Ruttmann E, Ulmer H, Vorarlberg Health, M., Promotion Program Study, G. Prospective
study of the association of gamma-glutamyltransferase with cancer incidence in women. Int J
Cancer. 2008; 123:1902–1906. [PubMed: 18688855]
Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, Licht JD,
Deberardinis RJ, Chandel NS. The proto-oncometabolite fumarate binds glutathione to amplify
ROS-dependent signaling. Molecular cell. 2013; 51:236–248. [PubMed: 23747014]
Sun WM, Huang ZZ, Lu SC. Regulation of gamma-glutamylcysteine synthetase by protein
phosphorylation. Biochem J. 1996; 320(Pt 1):321–328. [PubMed: 8947504]
Suzuki H, Kumagai H. Autocatalytic processing of gamma-glutamyltranspeptidase. J Biol Chem.
2002; 277:43536–43543. [PubMed: 12207027]
Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H,
Nakayama T, Suzuki Y, Sugano S, Sato E, Nagao T, Yokote K, Tatsuno I, Prives C. Phosphateactivated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive
oxygen species. Proc Natl Acad Sci U S A. 2010; 107:7461–7466. [PubMed: 20351271]
Takemura K, Kawachi H, Eishi Y, Kitagaki K, Negi M, Kobayashi M, Uchida K, Inoue J, Inazawa J,
Kawano T, Board PG. gamma-Glutamylcyclotransferase as a novel immunohistochemical
biomarker for the malignancy of esophageal squamous tumors. Hum Pathol. 2014; 45:331–341.
[PubMed: 24342434]
Tang F, Xie C, Huang D, Wu Y, Zeng M, Yi L, Wang Y, Mei W, Cao Y, Sun L. Novel potential
markers of nasopharyngeal carcinoma for diagnosis and therapy. Clinical biochemistry. 2011;
44:711–718. [PubMed: 21402064]
Tattoli I, Sorbara MT, Vuckovic D, Ling A, Soares F, Carneiro LA, Yang C, Emili A, Philpott DJ,
Girardin SE. Amino acid starvation induced by invasive bacterial pathogens triggers an innate
host defense program. Cell host & microbe. 2012; 11:563–575. [PubMed: 22704617]
Thompson GA, Meister A. Utilization of L-cystine by the gamma-glutamyl transpeptidase-gammaglutamyl cyclotransferase pathway. Proc Natl Acad Sci U S A. 1975; 72:1985–1988. [PubMed:
237267]
Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance.
Oncogene. 2003; 22:7369–7375. [PubMed: 14576844]
Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, Marinari UM, Domenicotti
C. Role of glutathione in cancer progression and chemoresistance. Oxidative medicine and
cellular longevity. 2013; 2013:972913. [PubMed: 23766865]
Tu Z, Anders MW. Identification of an important cysteine residue in human glutamate-cysteine ligase
catalytic subunit by site-directed mutagenesis. Biochem J. 1998; 336(Pt 3):675–680. [PubMed:
9841880]
Uejima D, Nishijo K, Kajita Y, Ishibe T, Aoyama T, Kageyama S, Iwaki H, Nakamura T, Iida H,
Yoshiki T, Toguchida J. Involvement of cancer biomarker C7orf24 in the growth of human
osteosarcoma. Anticancer Res. 2011; 31:1297–1305. [PubMed: 21508379]
Van Der Werf P, Griffith OW, Meister A. 5-Oxo-L-prolinase (L-pyroglutamate hydrolase).
Purification and catalytic properties. J Biol Chem. 1975; 250:6686–6692. [PubMed: 239948]
Van der Werf P, Orlowski M, Meister A. Enzymatic conversion of 5-oxo-L-proline (L-pyrrolidone
carboxylate) to L-glutamate coupled with cleavage of adenosine triphosphate to adenosine

Adv Cancer Res. Author manuscript; available in PMC 2015 July 27.

Liu et al.

Page 24

Author Manuscript
Author Manuscript
Author Manuscript

diphosphate, a reaction in the -glutamyl cycle. Proc Natl Acad Sci U S A. 1971; 68:2982–2985.
[PubMed: 5289242]
Van Der Werf P, Stephani RA, Meister A. Accumulation of 5-oxoproline in mouse tissues after
inhibition of 5-oxoprolinase and administration of amino acids: evidence for function of the
gamma-glutamyl cycle. Proc Natl Acad Sci U S A. 1974; 71:1026–1029. [PubMed: 4151516]
Wang W, Ballatori N. Endogenous glutathione conjugates: occurrence and biological functions.
Pharmacol Rev. 1998; 50:335–356. [PubMed: 9755286]
Watanabe T, Abe K, Ishikawa H, Iijima Y. Bovine 5-oxo-L-prolinase: simple assay method,
purification, cDNA cloning, and detection of mRNA in the coronary artery. Biological &
pharmaceutical bulletin. 2004; 27:288–294. [PubMed: 14993790]
Wellner VP, Sekura R, Meister A, Larsson A. Glutathione synthetase deficiency, an inborn error of
metabolism involving the gamma-glutamyl cycle in patients with 5-oxoprolinuria (pyroglutamic
aciduria). Proc Natl Acad Sci U S A. 1974; 71:2505–2509. [PubMed: 4152248]
Welsch DJ, Creely DP, Hauser SD, Mathis KJ, Krivi GG, Isakson PC. Molecular cloning and
expression of human leukotriene-C4 synthase. Proc Natl Acad Sci U S A. 1994; 91:9745–9749.
[PubMed: 7937884]
West MB, Chen Y, Wickham S, Heroux A, Cahill K, Hanigan MH, Mooers BH. Novel insights into
eukaryotic gamma-glutamyltranspeptidase 1 from the crystal structure of the glutamate-bound
human enzyme. J Biol Chem. 2013; 288:31902–31913. [PubMed: 24047895]
Williamson JM, Meister A. New substrates of 5-oxo-L-prolinase. The Journal of biological chemistry.
1982; 257:12039–12042. [PubMed: 6126479]
Willis MN, Liu Y, Biterova EI, Simpson MA, Kim H, Lee J, Barycki JJ. Enzymatic defects underlying
hereditary glutamate cysteine ligase deficiency are mitigated by association of the catalytic and
regulatory subunits. Biochemistry. 2011; 50:6508–6517. [PubMed: 21657237]
Winkler A, Njalsson R, Carlsson K, Elgadi A, Rozell B, Abraham L, Ercal N, Shi ZZ, Lieberman
MW, Larsson A, Norgren S. Glutathione is essential for early embryogenesis–analysis of a
glutathione synthetase knockout mouse. Biochem Biophys Res Commun. 2011; 412:121–126.
[PubMed: 21802407]
Yang Y, Dieter MZ, Chen Y, Shertzer HG, Nebert DW, Dalton TP. Initial characterization of the
glutamate-cysteine ligase modifier subunit Gclm(−/−) knockout mouse. Novel model system for
a severely compromised oxidative stress response. J Biol Chem. 2002; 277:49446–49452.
[PubMed: 12384496]
Yoshimoto T, Soberman RJ, Lewis RA, Austen KF. Isolation and characterization of leukotriene C4
synthetase of rat basophilic leukemia cells. Proc Natl Acad Sci U S A. 1985; 82:8399–8403.
[PubMed: 3866231]
Zhang W, Braun A, Bauman Z, Olteanu H, Madzelan P, Banerjee R. Expression profiling of
homocysteine junction enzymes in the NCI60 panel of human cancer cell lines. Cancer Res.
2005; 65:1554–1560. [PubMed: 15735045]
Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM,
Plunkett W, Keating MJ, Huang P. Stromal control of cystine metabolism promotes cancer cell
survival in chronic lymphocytic leukaemia. Nature cell biology. 2012; 14:276–286. [PubMed:
22344033]

Author Manuscript
Adv Cancer Res. Author manuscript; available in PMC 2015 July 27.

Liu et al.

Page 25

Author Manuscript
Figure 1. Structure of glutathione

GSH is a tripeptide composed of glutamate, cysteine, and glycine. Its γ-glutamyl peptide
bond makes it resistant to non-specific proteolytic cleavage.
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Figure 2. Functions of glutathione and enzymes that maintain redox homeostasis

Glutathione is maintained in a reduced state by the action of NADPH-dependent glutathione
reductase. Besides its role as a general antioxidant, GSH participates in biosynthetic
pathways, signaling processes, detoxification, storage and transport of key metabolites, and
sustains glutaredoxin (grx)-mediated reductive processes. Additional functions are described
in the text.
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Figure 3. Canonical γ-glutamyl cycle
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The γ-glutamyl cycle was initially proposed to describe the involvement of glutathione in
transpeptidation-dependent amino acid transport, as discussed in the text (Orlowski and
Meister, 1970). Since its initial description, GGCT has been suggested to use accumulated γglutamylcysteine as a substrate as well. A newly characterized enzyme, ChaC1, may provide
a route for the intracellular degradation of glutathione, producing 5-oxoproline and cysteinyl
glycine (not shown). *Please note that GGT is an ectoenzyme located at the plasma
membrane.
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Figure 4. Homology model of human GCL
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A homology model of human GCLC was generated from the closely related S. cerevisiae
GCL structure (Biterova and Barycki, 2009). Potential sites of post-translational
modifications as discussed in the text are illustrated in space filling representation. Docked
into the enzyme active site are ADP and the mechanism based inhibitor L-S,R-buthionine
sulfoximine (BSO), also in space filling representation. Colored atoms are as follows:
yellow, sulfur; red, oxygen; deep blue, nitrogen; orange, phosphorus; gray, carbon.
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Figure 5. Precursors of glutathione synthesis

Metabolic routes for the three amino acids needed for GSH biosynthesis are outlined and
color coded by amino acid provision pathways: yellow, cysteine, denotes intimate crosstalk
with methionine metabolism (Lu and Mato, 2012; Zhang et al., 2005); green, glycine, is
directly linked to carbohydrate, serine, and choline levels (Locasale, 2013); blue, glutamine/
glutamate, indicates coordination with proline and TCA cycle metabolites (Daye and
Wellen, 2012). Although not illustrated, one carbon metabolism links glycine metabolism
and methionine salvage pathways.
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